Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Xenon ( (XENE) ) has issued an announcement.
On June 30, 2025, Xenon Pharmaceuticals Inc. appointed Ian Mortimer, the company’s President and CEO, as the interim Chief Financial Officer following the resignation of Sherry Aulin. This leadership change is expected to maintain continuity in the company’s financial operations without altering Mortimer’s existing compensation.
The most recent analyst rating on (XENE) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
Xenon’s primary strengths lie in its strong financial position and positive clinical development progress, as highlighted in the earnings call. However, the absence of revenue and profitability, along with technical and valuation concerns, weigh heavily on the overall stock score.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapeutics.
Average Trading Volume: 1,305,123
Technical Sentiment Signal: Hold
Current Market Cap: $2.46B
Find detailed analytics on XENE stock on TipRanks’ Stock Analysis page.